



GLAND PHARMA LIMITED

July 20, 2026

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
25th floor, Dalal Street
Mumbai - 400 001
Scrip Code: 543245

National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor
Plot no. C-1, Block G, Bandra Kurla Complex
Bandra (East), Mumbai - 400 051
Symbol: GLAND (ISIN: INE068V01023)

Dear Sir/Madam,

Sub: Changes in Directorate

In compliance of the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"); and in continuation to our intimation dated June 18, 2026; We would like to inform you that the shareholders of the Company through postal ballot (e-voting) have inter-alia approved:

- Re-appointment of Mr. Udo Johannes Vetter (DIN: 00707474) as an Independent Director of the Company for the second term of five consecutive years, with effect from July 21, 2026 till July 20, 2031 and approved payment of Commission on profits as remuneration to him
- Appointment of Mr. William Robert Keller (DIN: 11593622), as an Independent Director of the Company for a period of five consecutive years with effect from June 15, 2026 till June 14, 2031 and approved payment of Commission on profits as remuneration to him

The voting results and the Scrutinizer's report on the Postal ballot e-voting were already filed with the Stock Exchanges.

The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are given in **Annexure-A** enclosed herewith.

This is for your information and records.

Yours truly,
For Gland Pharma Limited

Sampath Kumar Pallerlamudi
Company Secretary & Compliance Officer

Encl: As above

Annexure A

Details required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

Details of Mr. Udo Jahannes Vetter

Sl. No	Particulars	Remarks
1	Reason for change	Mr. Udo Jahannes Vetter, DIN: 00707474, who has been appointed as Independent Director of the Company for a period of five years with effect from July 21, 2021 to July 20, 2026 by the shareholders of the Company, in terms of Section 149 of the Companies Act, 2013; be and is hereby reappointed as an Independent Director of the Company for a second term of five consecutive years, with effect from July 21, 2026 till July 20, 2031.
2	Date of Change	Effective from July 21, 2026
3	Brief profile	Mr. Udo J. Vetter earned his degree in Clinical Pharmacy from the University of Washington and subsequently worked for five years as a Manufacturing Pharmacist at Schering-Plough Corp. (now Merck & Co., Inc.), where he was responsible for establishing production facilities in Puerto Rico. From 1985 to 1988, Mr. Udo J. Vetter served as Vice President, Licensing & Production, at Martec Inc., a generic pharmaceutical manufacturer based in Kansas City, Missouri, USA. During the late 1980s, he was President of the start-up company Vetter Pharma-Turm Inc. in Pennsylvania, USA. From 1987 to 1991, Mr. Udo J. Vetter served as Managing Director of Vetter Pharma. He subsequently held the position of Managing Director of Vetter Inject GmbH & Co. KG, the technical arm of the Vetter Group, from 1989 to 2003. Between 1999 and 2004, he was a member of the Executive Committee of Vetter Pharma Corporation. Since 1999, Mr. Udo J. Vetter has been a member of the Board of

		Directors of Vetter Pharma Corporation and has served as its Chairman since 2008. In 2004, Mr. Udo J. Vetter founded UV-Cap, an investment company focused on supporting mid-sized B2B businesses in the life sciences sector and acting as a long-term strategic partner to high-potential enterprises. He continues to serve as Managing Director of UV-Cap. Mr. Udo J. Vetter currently serves as Chairman of the ITM Group, Germany. He is a member of the International Society for Pharmaceutical Engineering (ISPE) and of the Global Pharmaceutical Manufacturing Leadership Forum (GPMLF). Following six years as President of the European Family Businesses (EFB) Association, he now serves as Vice-President of the organization. In addition, Mr. Udo J. Vetter served as Chairman of the University Council of the University of Albstadt-Sigmaringen until 2018 and was awarded the title of Honorary Senator in recognition of his contributions to the institution.
4	Disclosure of relationships between director	Not Applicable
5	Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-19 and the National Stock Exchange of India Limited Circular with ref. no. NSE/CML/2018/24, both dated June 20, 2018	Not Applicable

Details of Mr. William Robert Keller

SI. No	Particulars	Remarks
1	Reason for change	Mr. William Robert Keller, DIN: 11593622 was appointed as an Independent Director of the Company for a period of five consecutive years with effect from June 15, 2026 till June 14, 2031.
2	Date of Change	Effective from June 15, 2026
3	Brief profile	Mr. William Robert Keller, aged 78, is currently an Independent Director of Wuxi Biologics, a global Contract Research, Development and Manufacturing Organization (CRDMO) in Biologics, listed on Hongkong Stock Exchange. He is also an Independent Director on Hua Medicine, a Company listed on Hongkong Stock Exchange. During August, 2020 to August, 2025; Mr. William Keller was a Director of Cathay Biotech Inc, which is listed on Shanghai Stock exchange. He was the Chairman of Coland Pharmaceutical Co. Ltd (earlier listed on Taiwan Stock Exchange) for ten years till November, 2020. Earlier, from December, 2009 to May, 2015; he was an Independent Director on the Board of Alexion Pharmaceuticals Inc., a Nasdaq listed entity. For seven years, till December, 2014 Mr. William Keller was also an Independent Director of Taigen Biopharmaceutical Holding Limited, a Taiwan Stock Exchange listed company. Mr. William Keller has more than 40 years of experience in managing operations in South America and Asia, particularly in pharmaceutical and biotechnology sectors. Mr. Keller spent almost three decades in different management positions with Roche in South America and Asia. From 1990 to 1994, he served as the Managing Director of Roche Hong Kong with regional responsibilities, and subsequently from 1994 to 2003, he was the General Manager for Roche China Holding, and Shanghai Roche Pharmaceutical Ltd., where he established and built up the Roche business in China.

		In 2003, Mr. Keller founded Keller Pharma Consultancy, a pharmaceutical consulting firm focusing on market entry strategies for foreign biotech companies into the Chinese market and supporting biopharma start-up companies in Shanghai. During June, 1997 to December, 2013; Mr. Keller served as the Vice Chairman of the Shanghai Association of Enterprises with Foreign Investment, advising and supporting foreign invested companies as a business advisor. From March, 2003 to June, 2014; Mr. Keller was appointed as Deputy General Manager of Shanghai Zhangjiang Biotech and Pharmaceutical Base Development Co. Ltd, focusing on pharmaceutical and biotechnological industry development. From March, 2003 to December, 2013, he served as a Senior Consultant of the Shanghai Foreign Investment Development Board, providing advice regarding foreign investment development. From May, 2007 to April, 2010; Mr. Keller served as the Chairman of HBM Biomed China Partners Ltd., overseeing investments in biotechnology companies. Mr. Keller holds a Bachelor of Science degree from the School of Economics and Business Administration in Zurich, Switzerland, in July, 1972.
4	Disclosure of relationships between director	Not Applicable
5	Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-19 and the National Stock Exchange of India Limited Circular with ref. no. NSE/CML/2018/24, both dated June 20, 2018	Not Applicable